Tumor markers for HCC-screening in patients with liver cirrhosis and hepatic inflammation

Dominik Bettinger1, Michael Schultheiß2, Jonas Bürk2, Elisabeth Panther3, Eva Knüppel3, Robert Küper3, Robert Thimme2, Hubert E. Blum2, Hans Christian Spangenberg1

1 Dept. of Medicine II, University Hospital Freiburg, Germany; 2 Dept. of Radiology, University Hospital Freiburg, Germany; 3 Wako Chemicals GmbH, Neuss, Germany

Background and aims:
The incidence of hepatocellular carcinoma (HCC) is rising in the Western world especially due to chronic hepatitis C (HCV) infection. Screening for HCC is mainly based on ultrasound performance as tumor markers such as α-fetoprotein (AFP) are not recommended in the current AASLD guidelines. In patients with inflammatory active, HCV-associated liver cirrhosis, AFP is often elevated as a result of a high cell turnover resulting in impaired diagnostic accuracy. Other possible biomarkers are the lens culinaris agglutinin-reactive fraction of AFP (AFP-L3) and des-γ-carboxyprothrombin (DCP).
The aim of this study was to determine if AFP-L3 and DCP are influenced by hepatic inflammation.

Methods:
Serum samples of 93 patients with chronic HCV were prospectively collected. Patients with other liver diseases were excluded. 69 patients had liver cirrhosis without evidence of HCC. In 24 patients diagnosis of HCC was confirmed according the current AASLD guidelines. Hepatic inflammation was determined if alanin-aminotransferase (ALT) was elevated (> 50 U/l). AFP, AFP-L3 and DCP were measured using a micro-total analysis system (Wako Chemicals GmbH, Neuss, Germany). Diagnostic accuracy was evaluated using ROC analyses. Differences in biomarker values were determined by non-parametric tests.

Results:

<table>
<thead>
<tr>
<th>Liver cirrhosis</th>
<th>HCC</th>
<th>cut-off</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>AUC</th>
</tr>
</thead>
<tbody>
<tr>
<td>n=69</td>
<td>n=24</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Sex – no (%)  
male: 45 (65%)  
female: 24 (35%)  
Age – median (range):  
58 (32-80)  
71 (45 – 80)  
Child-Score  
A: 55 (81%)  
B: 9 (13%)  
C: 4 (6%)  
BCLC  
A: -  
B: 14 (58%)  
C: 5 (21%)  

Table 1: Baseline characteristics of patients with HCV-associated liver cirrhosis and HCC. #2 patients (8%) with HCC had no liver cirrhosis.

<table>
<thead>
<tr>
<th>Liver cirrhosis</th>
<th>HCC</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>n=69</td>
<td>n=24</td>
<td></td>
</tr>
</tbody>
</table>

AST [U/l]  
45 (25-206)  
98 (29-226)  
0.065  
ALT [U/l]  
65 (19-208)  
69 (17-248)  
0.507  

AFP [ng/ml]  
6.8 (1.4 - 265.6)  
21.7 (0.8 - 149413.8)  
0.005  
AFP-L3 [%]  
4.1 (0 - 26.9)  
15.7 (0 - 90.7)  <0.001  
DCP [ng/ml]  
0.29 (0 - 1.9)  
2.09 (0.16 - 1835.60)  <0.001  

Table 2: ROC analyses stratified according to elevation of ALT indicating hepatic inflammation.

Fig. 2: False positive rate of AFP, AFP-L3 and DCP in patients with elevated ALT compared to those without elevation.

Conclusions:
Hepatic inflammation indicated by elevated ALT results in elevated AFP values. Therefore AFP may be an insufficient screening tool in patients with inflammatory active liver cirrhosis. AFP-L3 and DCP are not influenced by hepatic inflammation. These two biomarkers may provide better diagnostic accuracy in these patients and may compensate the limitations of AFP.